United States > Blood & Urine Collection

LabNotes - Volume 17, No. 1, 2006

Industry News

BD (Becton, Dickinson and Company) (NYSE: BDX) has announced the purchase of Burlington, NC-based TriPath Imaging (Nasdaq: TPTH), makers of an automated diagnostic test for cervical cancer screening (Pap smear). TriPath develops and markets innovative solutions for the clinical management of cancer, including detection, diagnosis, staging, and treatment. As cancer remains a leading worldwide health concern, this acquisition expands the BD scope of expertise in the areas of cancer diagnostics, disease state management, and next-generation medical technologies.

sidebar

IN THIS ISSUE

	From the Editor
	FEATURE Preanalytical Errors in the Emergency Department
	Differences in Composition of Capillary and Venous Blood Specimen
	New Information About Safety
	Industry News BD has announced the purchase of Burlington, NC-based TriPath Imaging
	Product News New Tube Coming Soon
	Introducing BD Microtainer® Contact-Activated Lancet
	CLMA Scholarship Opportunuties
	See us at CLMA
	BD Values your opinion...Take the LabNotes on-line survey
	Urine Test Survey Results
	Web-Based Seminars
	BD Vacutainer® Brand and Trademark
	Subscribe
	Download this issue
	View previous issues

For questions regarding our Blood, Urine collection, or other sample collection products and services please contact us.

This publication is a service to the customers and friends of BD, and is designed only to provide general information. It is not intended to be comprehensive or provide any legal or medical advice.